Quintiles' three service groups will now have six lines of business. These six units will focus on key areas of service to the healthcare industry. Each unit is led by an experienced executive reporting to Dennis Gillings, Ph.D., Chairman and Chief Executive Officer of Quintiles Transnational.

"Our new structure reflects key drivers of our industry - the need to rapidly assess the viability of the burgeoning number of new drugs, cost-effectively accelerate development of the most promising drugs, quickly launch new medicines and evaluate their impact on healthcare," Gillings said. "To complement our four existing units, we've formed two new units - Early Development and Laboratory Services, and Quintiles Integrated Strategic Solutions.

"Each of our six units focuses on an important aspect of service delivery to the healthcare industry, while maintaining our integrated approach to complete outsourcing solutions for our customers. I believe this new structure positions the company for future growth and allows us to respond more quickly to customer needs and allocate resources more efficiently."

The service groups and their lines of business are:

Product Development -
* Early Development and Laboratory Services. This unit includes Quintiles' worldwide preclinical, clinical trial materials manufacturing and packaging, laboratory and Phase I operations. Led by Joseph P. Clancy, CEO;
* Clinical Development Services. This unit includes Phase II and III clinical trials operations. Led by Ludo Reynders, CEO.

Commercial Development -
* Quintiles Integrated Strategic Solutions. This unit focuses on strategies and services that bridge Product Development, Commercialization and QUINTERNET (TM) Informatics. It includes Quintiles Advanced Phase Solutions; Quintiles Consulting; The Lewin Group; and Quintiles Medical Communications. Led by Richard Johnson, M.D., CEO;
* Quintiles Commercialization. This includes Innovex sales and marketing services. Led by James Mauzey, CEO.

QUINTERNET(TM) Informatics -
* ENVOY Corporation. ENVOY provides electronic healthcare transactions processing. Led by Jim Kever, CEO;
* Quintiles Informatics. This unit provides unique market research and healthcare information to pharmaceutical and healthcare customers. Led by Gregory Porter, CEO.

"The new leaders I'm announcing today, Joe Clancy and Rich Johnson, each bring a wealth of experience in both business management and technical operations to add value to our customers' businesses by accelerating drug development and market penetration," Gillings said.

Clancy was most recently President of Quintiles Product Development, Europe. Prior to that, he was a Group Vice President responsible for a number of therapeutic specialty areas and services. Clancy was on BRI International's Board of Directors from 1985 to 1996, when BRI was acquired by Quintiles. Clancy received his law degree from Fordham University and his master's in business administration from Cornell University.

Johnson co-founded Q.E.D. International, an integrated product marketing and communication company that joined Quintiles in October 1998. Succeeding Johnson as President of Q.E.D. is Robert Blink, also a co-founder of Q.E.D.

Johnson has held senior positions in clinical research, medical education, new product development, and marketing at a major pharmaceutical company. He received his medical degree from Mount Sinai School of Medicine in New York City and graduate business training from Columbia University's Executive Management Program.

Also today, Reynders announced the appointment of Joseph J. Colatuno to President, Clinical Development Services, Quintiles Americas. Colatuno will oversee North and South American business operations. He will report to Reynders.

Colatuno joined Quintiles in 1998 as Senior Vice President of Corporate Development, Quintiles Americas. Prior to that, Colatuno was Vice President and General Manager, The Americas, for ClinTrials Research Inc. He also spent 20 years at The Upjohn Company in increasingly responsible sales and operations positions. Colatuno received his bachelor's degree in economics and business administration from Wagner College in New York City.

Quintiles Transnational Corp. is the market leader in providing a full range of integrated product development and commercialization solutions to the pharmaceutical, biotechnology and medical device industries. Quintiles also is a leader in electronic transactions processing and informatics for the healthcare sector and provides healthcare policy consulting to governments and other organizations worldwide.

Headquartered near Research Triangle Park, North Carolina, Quintiles is a member of the S&P 500, Fortune 1000 and Nasdaq 100. With more than 20,000 employees worldwide and offices in 31 countries, Quintiles operates through specialized units dedicated to meeting customers' individual needs. Visit the Quintiles Transnational Web site at www.quintiles.com.